Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A-Reference-Cited by-同舟云学术

Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A

Published:2017-04-03 Issue:3 Volume:34 Page:146-156
ISSN:0888-0018
Container-title:Pediatric Hematology and Oncology
language:en
Short-container-title:Pediatric Hematology and Oncology

Author:

Zhao Yongqiang¹,Xiao Juan¹,Yang Renchi²,Wu Runhui³,Hu Yu⁴,Beckmann Horst⁵,Wu Junde⁶,Hou Qingsong⁶,Sun Jing⁷

Affiliation:

1. Peking Union Medical College Hospital, Beijing, China

2. Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

3. Beijing Children's Hospital and Capital Medical University, Beijing, China

4. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

5. Bayer AG, Wuppertal, Germany

6. Bayer, Beijing, China

7. Nanfang Hospital, Southern Medical University, Guangzhou, China

Publisher

Informa UK Limited

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://www.tandfonline.com/doi/pdf/10.1080/08880018.2017.1313921

Reference20 articles.

1. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy

2. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

3. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

4. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

5. Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapy

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Noninterventional study assessing joint health in persons with hemophilia A after switching to turoctocog alfa pegol: design of pathfinderReal;Research and Practice in Thrombosis and Haemostasis;2024-02

2. Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India;Hematology;2023-11-07

3. Effectiveness of Prophylactic Coagulation Factor Replacement Therapy in Patients with Severe Hemophilia A in Taiwan – A Population-Based Study;Clinical Epidemiology;2022-12

4. The long‐term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia A in China: Population‐based predictions from 2018 to 2033;Haemophilia;2022-06-17

5. Value of Contrast-enhanced Ultrasound in Evaluating Synovitis and Predicting Recurrent Joint Bleeding of Hemophilia;Current Medical Science;2022-03-15